4//SEC Filing
Gresham Gwendolyn 4
Accession 0000950170-25-001314
CIK 0001958086other
Filed
Jan 2, 7:00 PM ET
Accepted
Jan 3, 4:57 PM ET
Size
8.5 KB
Accession
0000950170-25-001314
Insider Transaction Report
Form 4
Transactions
- Exercise/Conversion
Common Stock
2024-12-31+9,604→ 33,564 total - Exercise/Conversion
Performance Shares
2024-12-31−9,604→ 0 totalExercise: $0.00→ Common Stock (9,604 underlying) - Tax Payment
Common Stock
2024-12-31$17.31/sh−5,989$103,670→ 27,575 total
Footnotes (1)
- [F1]These shares were awarded as restricted performance shares in February 2022, as disclosed in the Reporting Person's Form 4 filing on February 17, 2022. The Company finished in the 52nd percentile of return on invested capital among the Bloomberg Peer Group at the conclusion of the performance period on December 31, 2024. Therefore, the performance criteria and requirements for vesting have been satisfied at 54.6% of the target award level, and such number of shares vested on December 31, 2024.
Documents
Issuer
Core Laboratories Inc. /DE/
CIK 0001958086
Entity typeother
Related Parties
1- filerCIK 0001842114
Filing Metadata
- Form type
- 4
- Filed
- Jan 2, 7:00 PM ET
- Accepted
- Jan 3, 4:57 PM ET
- Size
- 8.5 KB